Literature DB >> 27394077

Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis.

Ifeoma Okwor1, Jude E Uzonna2.   

Abstract

Leishmaniasis affects millions of people worldwide and continues to pose public health problem. There is extensive evidence supporting the critical role for IL-12 in initiating and maintaining protective immune response to Leishmania infection. Although gene deletion studies show that CD40-CD40L interaction is an important pathway for IL-12 production by antigen-presenting cells and subsequent development of protective immunity in cutaneous leishmaniasis, several studies have uncovered other pathways that could also lead to IL-12 production and immunity in the absence of intact CD40-CD40L signaling. Here, we review the literature on the role of IL-12 in the induction and maintenance of protective T cell-mediated immunity in cutaneous leishmaniasis and the different pathways leading to IL-12 production by antigen-presenting cells following Leishmania major infection. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD40; CD40 ligand; IL-12; Immunity; Infection; Leishmania major; Macrophage antigen 1; Th1 response

Mesh:

Substances:

Year:  2016        PMID: 27394077     DOI: 10.1016/j.cellimm.2016.06.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  6,7-Dehydroroyleanone diterpene derived from Tetradenia riparia essential oil modulates IL-4/IL-12 release by macrophages that are infected with Leishmania amazonensis.

Authors:  Mariana de Souza Terron-Monich; Izabel Galhardo Demarchi; Pollyanna Rina Ferreira da Silva; Áquila Carolina Fernandes Herculano Ramos-Milaré; Zilda Cristiani Gazim; Thaís Gomes Verzignassi Silveira; Maria Valdrinez Campana Lonardoni
Journal:  Parasitol Res       Date:  2018-12-05       Impact factor: 2.289

Review 2.  Melittin as a promising anti-protozoan peptide: current knowledge and future prospects.

Authors:  Hamed Memariani; Mojtaba Memariani
Journal:  AMB Express       Date:  2021-05-13       Impact factor: 3.298

Review 3.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

4.  Host-parasite Responses Outcome Regulate the Expression of Antimicrobial Peptide Genes in the Skin of BALB/c and C57BL/6 Murine Strains Following Leishmania major MRHO/IR/75/ER Infection.

Authors:  Hamid Daneshvar; Amir Tavakoli Kareshk; Iraj Sharifi; Alireza Keyhani; Razieh Tavakoli Oliaee; Arash Asadi
Journal:  Iran J Parasitol       Date:  2018 Oct-Dec       Impact factor: 1.012

5.  miR-21 Expression Determines the Early Vaccine Immunity Induced by LdCen -/- Immunization.

Authors:  Sreenivas Gannavaram; Parna Bhattacharya; Abid Siddiqui; Nevien Ismail; Subha Madhavan; Hira L Nakhasi
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

6.  Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens.

Authors:  Ghodratollah Salehi-Sangani; Mehdi Mohebali; Vahid Jajarmi; Ali Khamesipour; Mojgan Bandehpour; Mahmoud Mahmoudi; Hadi Zahedi-Zavaram
Journal:  Iran J Basic Med Sci       Date:  2019-12       Impact factor: 2.699

Review 7.  Unraveling the Role of Immune Checkpoints in Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Esther von Stebut
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

Review 8.  β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease.

Authors:  Monika Bednarczyk; Henner Stege; Stephan Grabbe; Matthias Bros
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

9.  Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis.

Authors:  Camilla Heldbjerg Drabe; Rasmus L Marvig; Line Borgwardt; Jens D Lundgren; Hanne Vibeke Hansen Maquart; Terese Lea Katzenstein; Marie Helleberg
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.